Antiphospholipid syndrome (APL syndrome) can be called "acquired antibody-mediated thrombophilia" from the clinical point of view. The hypercoagulability/thrombotic diathesis of APL syndrome can manifest in a wide variety of clinical and/or laboratory abnormal states. The expanding heterogeneous spectrum of the disorder varies from a coincidental abnormality in the hemostasis laboratory to thromboembolic events such as a serious stroke, venous thrombosis, arterial occlusion, or a catastrophic obstetrical complication in the clinic (1) .
There are many obscurities challenging a better understanding of APL syndrome and APL antibody-associated pathologic states. Difficulties are mainly present in the confusing terminology describing the disorders and antibodies, problems in the hemostasis laboratory and their clinical relevance, still ongoing revisions in the diagnostic criteria, heterogeneous patient presentations, chaotic multisystemic involvement, unsatisfactory treatment strategies, and, of course, the unresolved enigmatic distinct etiopathogenesis of the APL syndrome. The aim of this review is to outline current dilemmas and their present clarifications in the wide clinicopathologic spectrum of APL syndrome and APL antibody-related distinct pathologic conditions.
DIFFICULTIES IN THE CURRENT TERMINOLOGY OF THE APL SYNDROME
The term "APL antibodies" represents a heterogeneous group of antibodies associated with a prothrombotic state and/or a condition with high risk of recurrent fetal loss. Currently no single assay can identify every APL antibody. While the presence of those antibodies is detected with a phospholipid-dependent coagulation reaction, they are designated as "lupus anticoagulants" (LA). When they are demonstrated with the solid phase enzyme-linked immunosorbent assay (ELISA) in which microplate wells are coated with cardiolipin, they are called "anticardiolipin antibodies" (ACA). Therefore, ACAs are detected by their antigenic specificity irrespective of their functional properties. On the other hand, LAs are detected by their effect on in vitro coagulation irrespective of their immunologic target.
Despite the famous historical name of the syndrome, the real antigenic target for APL antibodies is not phospholipid itself but some phospholipid binding plasma proteins, mainly beta 2 glycoprotein-1 (β 2 GP-1) and prothrombin. β 2 GP-1 is required for the binding of autoimmune ACAs to cardiolipin. Most LAs depend on the presence of prothrombin or β 2 GP-1 directed against anionic phospholipids (1) (2) (3) (4) (5) (6) (7) (8) . Furthermore, the anionic phospholipids probably play important roles for the binding of APL antibodies to those phospholipid binding plasma proteins in in vivo conditions. It is not clear whether these antibodies recognize the proteins themselves, the phospholipid-protein complex, or neo-or cryptic antigens eventually expressed as a result of the interactions. Another hypothesis is that close contact to the negatively charged surface makes clusters, providing higher antigenic density for the binding of the APL antibodies that have low affinity for binding under normal conditions (3, (7) (8) (9) (10) (11) (12) (13) . Because APL antibodies represent a heterogenous group, each of those hypotheses could be operative in different patients.
ACAs and LAs represent two intersecting, but non-identical, subsets of autoantibodies. Thus, LACs and ACAs may coexist or may occur independently (14) (15) (16) . From the clinical point of view, there are some patients with recurrent venous and/or arterial thromboses without APL antibodies via with those "routine" assays in the absence of other autoimmune diseases. However they have positivity for the more recently recognized "subgroups" of APL antibodies (i.e. antibodies against β 2 GP-1, prothrombin, or annexin-V, and antibodies against phospholipids themselves other than cardiolipin including phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, and phosphatidylcholine) (17) (18) (19) (20) . The term "APL antibody" describes either of those previously mentioned antibodies, whereas the term "APL syndrome" designates the presence of either of those "APL antibodies" together with the thrombotic manifestations and/or recurrent fetal loss and/or thrombocytopenia (Fig. 1) .
The term "LA" is improper for two major aspects. First, the "LA" antibodies are not necessarily specific to patients with systemic lupus erythematosus (SLE). Many patients suffering from recurrent thrombotic events or obstetrical complications and are positive for LA do not manifest any of the major clinical or serologic features of SLE. Second, LAs prolong the in vitro coagulation assays but actually demonstrate procoagulant, not anticoagulant, effects in in vivo conditions. APL antibodies can be associated with clinical features of APL syndrome without any finding of an underlying connective tissue disorder (i.e., primary APL syndrome). APL syndrome can also complicate the clinical course of various connective tissue disorders, most commonly SLE (18,21-28), as well as some other autoimmune disorders such as Sjögren's syndrome, rheumatoid arthritis, systemic sclerosis, systemic vasculitis, or dermatomyositis (23). APL syndrome, however, more commonly develops in patients without any underlying disorder (18,23,26-29).
Presence of LA or ACAs generally defines two distinct patient populations, each of which is associated with an increased risk of thrombosis (15, 18) . However, there appears to be an intense overlap between those disorders, challenging widespread use of the LAs and APL antibodies together. Therefore, we prefer to present those two disorders together for the sake of clarity in this paper.
Infection-or Drug-Related APL Antibodies APL antibodies are reported to occur in some infections such as syphilis, malaria, infectious mononucleosis, tuberculosis, human immunodeficiency virus, and hepatitis A, B, and C (30-32). Infection-related ACAs tend to be transient, of low titre, and directly bind to the cardiolipin itself; i.e., they are not β 2 GP-1 dependent, and moreover could be inhibited by β 2 GP-1 (30,31). In these conditions, there is generally no apparently increased risk for developing manifestations of APL syndrome (1, 32) , although certain viral infections can precede the development of APL syndrome (33-36).
Some drugs are associated with APL antibodies and LA activity. Procainamide hydrochloride, quinidine sulfate, phenytoin sodium, chlorpro-mazine hydrochloride, valproic acid, amoxicillin, hydralazine hydrochloride, and propranolol hydrochloride are all reported for this association. Those drug-induced APL antibodies were associated with thrombotic complications in contrast to the majority of infectious-related ACAs (15, 18) .
PATHOBIOLOGY AND GENESIS OF APL SYNDROME: AN ENIGMA FROM MOLECULES TO DISEASE
Pathobiology and genesis of the APL syndrome still remain undetermined. However, there have been enormous efforts and progress for our understanding the molecular pathogenesis of the APL syndrome in the past decade.
The role of APL antibodies as the "primary cause" of the syndrome could be questionable, at least for some patients. APL antibodies are increased in patients with autoimmune hemolytic anemia (37). The APL antibodies, thus, could be "innocent bystanders" generated secondary to antibody-mediated cell injury in some disorders.
Another possibility is that APL antibodies could act as a "second hit," and could be both an effect and a cause of thrombosis. In that hypothetical model, anionic phospholipids that are exposed during blood clotting could trigger immunological recognition and the formation of APL antibodies, promoting a vicious cycle through their thrombogenic properties (38) . Finally, the APL antibodies could play direct causal roles in the generation of the clinical features of APL syndrome. There are data supporting this final hypothesis. The majority of antigenic structures that are targets for the APL antibodies do play roles in the normal hemostasis. Moreover, those APL antibodies precede the thrombotic events, and the risk of developing the clinical manifestations of the APL syndrome correlates directly with the level of the APL antibodies (39-46). Furthermore, passive transfer of immunoglobulins from patients with APL syndrome generates features of APL syndrome in animal models (47-53). Therefore, rather than being merely an epiphenomenon, APL antibodies seem to play direct roles in the pathogenesis of APL syndrome. Although the exact pathogenetic mechanism(s) remain to be determined, it is likely that more than one mechanism could be operative for the development of the clinical manifestations because a wide spectrum of autoantibodies have been shown to be associated with the APL syndrome. Thrombotic events in patients with APL syndrome segregate into venous or arterial vascular tree. Arterial events are generally followed by arterial events and venous events by venous events in the majority of the cases in APL syndrome (54). Therefore, molecular mechanisms of thrombosis could differ in different clinical manifestations. For instance, venous thrombotic manifestations may be attributed to coagulation factor-associated mechanisms (i.e., secondary hemostasis), whereas disorders of platelets (i.e., primary hemostasis) might be responsible for arterial thromboses.
The β 2 GP-1 protein is the most frequently observed protein cofactor in the APL syndrome. However little is known regarding the physiologic role(s) of this protein. The β 2 GP-1 has been identified as a constituent of chylomicrons, and very-low-density and high-density lipoproteins. Roughly 40% of the circulating β 2 GP-1 is bound to lipoproteins. Therefore this protein may be involved in lipoprotein metabolism (55). β 2 GP-1 may also play a scavenging role in mediating the clearance of foreign particles and apoptotic cells in the circulation (56-58). β 2 GP-1 was also suggested as a natural anticoagulant. Circulating levels of β 2 GP-1 are reduced dramatically during disseminated intravascular coagulation (DIC) along with reductions in other anticoagulant proteins including protein C and antithrombin III. These data suggest specific consumption of the β 2 GP-1 during in vivo coagulation (59). A number of in vitro studies also supported the anticoagulant role of the β 2 GP-1 molecule. β 2 GP-1 can inhibit various platelet functions (60,61), downregulate the activation of the Hageman factor and the contact phase system of the coagulation cascade (62,63), prevent the binding of protein S with its plasma inhibitor, the C4b-binding protein (64), and inhibit tissue factor activity (65). However, the clinical relevance of those in vitro observations remains questionable because hereditary deficiency of β 2 GP-1 does not seem to be associated with thrombophilia (66). The β 2 GP-1 molecule can bind to negatively charged macromolecules that are involved in the initiation of coagulation. However, its binding affinity is far below that of many other phospholipidbinding proteins (67). Therefore, it seems un-likely that the binding of β 2 GP-1 can neutralize the initiation of coagulation cascade. Likewise, anti-prothrombin antibodies do not interfere with the coagulant properties of the prothrombin molecule itself (68). Both anti-β 2 GP-1 antibodies and anti-prothrombin antibodies can display LA activity (2, (4) (5) (6) 68) . Hence, other than direct inhibition of function, binding of those antibodies to their targets should have some common dynamic influences on the coagulation cascade.
Disruption of the Annexin V Shield in APL Syndrome
Annexin V is found in a variety of tissues including the vascular endothelium and placenta. This protein could have potent anticoagulant properties based on its high affinity for anionic phospholipids. The capacity of annexin V to displace coagulation factors from phospholipid surfaces is evident (69,70). A number of consecutive experiments supported this hypothesis. The decrements in the levels of annexin V induced by APL antibodies were accompanied by a shortening of the coagulation time of plasma. Likewise incubating endothelial cells with anti-annexin V resulted in faster coagulation of plasma. Moreover, removing annexin V from the cell surface by calcium chelator EGTA significantly accelerated the coagulation of plasma. Adding exogenous annexin V increased the coagulation time of plasma applied to the cells (69). APL antibodies directly reduced binding of annexin-V to noncellular anionic phospholipid-coated surfaces in a β 2 GP-1-dependent manner interfering with its anticoagulant activity, resulting in the acceleration of coagulation (70). Inhibition of annexin V binding to procoagulant phospholipid surfaces by APL antibodies was dependent upon anti-β 2 GP-1 antibodies. This reduction is significantly correlated with clinical thrombosis (71). The hypothesis depending on these data is used to explain the in vivo procoagulant and in vitro anticoagulant effects of APL antibodies. Based on the hypothesis, annexin V forms a crystal lattice over the anionic phospholipid surface that serves and shields it from the availability for the assembly of the phospholipid-dependent coagulation complexes (i.e. tissue factor, factor X, factor IX, factor V, etc.) under physiologic conditions. Annexin V, thus, has a potent anticoagulant effect in vivo. During the absence of the annexin V, the complexes of APL antibodies and their antigenic targets such as β 2 GP-1 or prothrombin, bind the phospholipid bilayer, reducing the access of coagulation factors to anionic phospho-lipids in vitro. Because there is a limiting quantity of anionic phospholipids, this interaction results in the prolongation of the coagulation assay. However, in in vivo conditions where there is sufficient amount of annexin V, the APL antibodies disrupt the ability of annexin V to form ordered crystals on the phospholipid surface and inhibit the anticoagulant effect of annexin V. That state results in a net increase of the amount of anionic phospholipid available for promoting coagulation reactions, which establishes a hypercoagulable state (38, 70) . This attractive hypothesis could link the paradoxical LA phenomenon and the in vivo thrombogenic tendency of the APL antibodies. However, there is some conflicting data. In a Russell's viper venom assay, co-incubation of annexin V with APL antibody containing plasma failed to correct the clotting time, but even caused prolongation of the clotting time. The observed clotting time exceeds that with either annexin V or APL containing plasma alone (72). Moreover, annexin V binding was unaffected by the presence of ACA-β 2 GP-1 complexes. Annexin V pre-adsorbed to the bilayers completely prevented adsorption of ACAβ 2 GP-1 complexes. None of the pre-adsorbed annexin V was displaced by ACA-β 2 GP-1 complexes (73). Therefore, displacement of the annexin V shield is not a prerequisite for the thrombotic events in patients with APL syndrome.
Inhibition of the Protein C Anticoagulant Pathway in APL Syndrome
The protein C anticoagulant pathway is a major regulatory mechanism of the coagulation cascade. Upon binding of thrombin to thrombomodulin, the thrombin molecule loses its procoagulant properties and cleaves protein C. Activated protein C then complexes with protein S and proteolyzes coagulation factors Va and VIIIa (74). A missense mutation in the factor V gene (1691 G→A) (Leiden mutation) is a common cause of thrombotic tendency by causing an abnormal factor V product. However, factor V Leiden mutation is not common in patients with APL syndrome (75). On the other hand, some patients with APL syndrome and asymptomatic carriers of APL antibodies may have acquired free protein S deficiency (76,77). Immunoglobulin fractions isolated from patients with APL causes acquired activated protein C resistance (78,79). The presence of LAs can interfere with the protein C pathway (80-83). Other APL antibodies, including anti-β 2 GP-1 antibodies and ACAs, were also associated with the acquired activated pro-tein C resistance phenomenon (84-86). ACAs bound to protein C in the presence of cardiolipin and β 2 GP-1, but not in the absence of either β 2 GP-1 or cardiolipin. These data suggest that protein C could be a target of ACA by making a complex with cardiolipin and β 2 GP-1, leading to protein C dysfunction (87). Autoantibodies generated against the isolated components of the protein C pathway (i.e. thrombomodulin, protein C, or protein S) may also impair the protein C pathway (88,89). Different steps in the protein C anticoagulant pathway could be targets for APL antibodies. They can inhibit thrombin formation. APL antibodies interfere with the protein C activation via thrombin-thrombomodulin complex. Inhibition of the protein C complex assembly takes place. Protein C activity can be downregulated directly or via inhibition of the activity of its cofactor, protein S. Finally, the antibodies directed against the substrates of APC, factors Va and VIIIa may protect them from inactivation (90,91).
A subpopulation of APL antibodies selectively inhibits the activated protein C complex as a result of differences in the phospholipid requirements of this complex as compared to those of the procoagulant complexes. Phosphatidylethanolamine supports activated protein C anticoagulant activity but has little influence on prothrombin activation. The inhibitory effect of LAs on activated protein C pathway was also enhanced in the presence of phosphatidylethanolamine (92). The rate of inhibition of the anticoagulant pathway (i.e., inactivation of factor Va) is much higher than the inhibition of the procoagulant pathway (i.e., thrombin generation) in the presence of phosphatidylethanolamine in the system (92). Therefore, differences between membrane phospholipid requirement of the anticoagulant and procoagulant reactions could account for the selective inhibition of one pathway over the other. The variability of different LA assays may be attributed to the differences in the phospholipid reagents inside them (93). Why the autoantibodies directed against the phospholipids themselves can cause hypercoagulability is possibly explained via this hypothesis.
Taken together, those observations suggest that inhibition of the activated protein C anticoagulation system may be a common mechanism contributing to the prothrombotic state of APL antibodies in at least a subgroup of patients.
APA and Endothelium
Vascular endothelial cells play a critical protective role in the whole body defense against thrombosis. Other than being a mechanical barrier, the endothelium plays an active role in the physiologic regulation of hemostasis through synthesis of numerous procoagulant and anticoagulant mediators. Immunologic injury to endothelial cells and alterations of the endothelial cell functions could have a place in the pathogenesis of the APL syndrome. Binding of APL antibodies suppressed vasodilator prostacyclin release by vascular endothelium. This inhibition generates an imbalance between vasodilator and vasoconstrictor prostoglandins toward the vasoconstrictor state (94). Likewise, urinary excretion of the major thromboxane metabolite of platelet origin (11-dehydro-thromboxane B2) is very significantly increased while the urinary metabolite reflecting the vascular production of prostacyclin (2,3-dinor-6-keto-prostaglandin F1 alpha) is much less enhanced (95). LAs induce apoptosis in endothelial cells (96,97). Apoptotic cells expose phosphatidylserine on the outer surface of the plasma membrane, further activating coagulation cascades (98). APL antibodies induce the production of monocyte chemoattractant protein-1 in human umbilical vein endothelial cells in a β 2 GP-1-dependent manner, which might in turn promote thrombus formation either by enhancing the influx of monocytes to the endothelium or by increasing tissue factor expression in monocytes (99). Binding of APL antibodies to the endothelial cell surface generates a functional cell activation and a procoagulant state. APL antibodies induce upregulation of certain cell adhesion molecules on the surface of endothelial cells. E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intracellular adhesion molecule-1 (ICAM-1) are mediated through β 2 GP-1 (100-103). Anti-β 2 GP-1 antibodies also significantly increase the secretion of proinflammatory cytokine IL-6 and augment prostacyclin metabolism by endothelial cells in a dose-dependent manner (100). APL antibodies increase leukocyte adhesion to the endothelium and enhance thrombus formation as demonstrated in an in vivo model of leukocyte adhesion and microcirculation. This increment was accompanied by enhanced adhesion molecule expression as an in vitro marker of endothelial cell activation (104). Circulating VCAM-1 is increased in patients with primary APL syndrome, which is further evident in patients with repeated thrombotic events (105). APL antibody induced endothelial activation and enhanced thrombosis is impaired in ICAM-deficient and ICAM-1/P-selectin deficient mice. These data demonstrate that pathogenic ef-fects of APL antibodies could be mediated by those cell adhesion molecules (106). Moreover, leukocyte adhesion to endothelial cells was significantly decreased after infusion of anti-VCAM-1 antibodies (106). Taken together, those data strongly indicate that pathologic activation of the endothelium may contribute to the hypercoagulable state of APL syndrome.
The Tissue Factor Pathway in APL Syndrome
Tissue factor (TF) is the principle (patho)biologic initiator of the coagulation cascade. Endothelial cells and monocytes can generate tissue factor upon stimulation by various substances. Tissue factor is inducibly synthesized in endothelium and monocytes (107).
Tissue factor pathway is upregulated in the APL syndrome. Plasma tissue factor is higher in patients with APL syndrome compared to healthy people and patients with thrombosis without APL antibodies (108,109). Cell surface expression of tissue factor and tissue factor mRNA levels are also increased in the monocytes of APL syndrome. These data suggest that circulating monocytes in APL syndrome express increased amounts of tissue factor (109,110). Moreover, APL antibodies induce tissue factor generation and enhance tissue factor activity in monocytes and vascular endothelial cells (108,111-113). On the other hand, APL antibodies can also interfere with the inhibitory activity of tissue factor pathway inhibitor in a group of patients (114,115), despite the circulating tissue factor pathway inhibitor levels were increased in APL syndrome (108). The increased levels of tissue factor pathway inhibitor could either reflect a compensatory response or endothelial activation or damage (108). Therefore, enhancement of the tissue factor pathway either by increasing tissue factor generation and activity or by interfering with its inhibition can be an important mechanism that leads to activation of coagulation and thrombus formation in the APL syndrome.
Molecular Mimicry as a Potential Triggering Mechanism in APL Syndrome
Immunization with phospholipids alone does not induce the production of APL antibodies (116). However, immunization of normal mice and rabbits with purified β 2 GP-1 induced production of high levels of APL antibodies in addition to antibodies against β 2 GP-1 (117-119). Characteristics of those β 2 GP-1-induced APL antibodies were similar to those of the human autoimmune APL antibodies (118,119). Moreover, immunization with β 2 GP-1 induced the development of the clinical and histopathologic features of APL syndrome in PL/J mice, which are genetically predisposed to autoimmune disease (120).
A major PL-binding site of β 2 GP-1, called GDKV, induced production of pathogenic APL antibodies alone without the rest of the β 2 GP-1 molecule (121). Some common human viruses shared structural similarities with this phospholipid-binding region of β 2 GP-1, the GDKV. Those peptides showed greater degrees of binding to PL compared to GDKV. Interestingly, immunization of mice with those peptides caused production of high levels of APL antibodies (122). A CMV peptide-induced monoclonal APL antibody showed significantly high binding to cardiolipin and varying degrees of binding to other phospholipids in the presence of β 2 GP-1. Injection of those monoclonal APL antibodies in mice resulted in a significant increase in the number of leukocytes adhering to endothelial cells and enhanced thrombus formation in vivo. These data suggest that those antibodies could be pathogenic (123). Certain viral infections can precede the development of APL syndrome (32-36). Taken together, those experiments proposed that the tolerance to self β 2 GP-1 could be broken after certain microbial exposure by molecular mimicry. This mechanism could be operative in at least a subgroup of APL patients (124). A wide variety of diseases and immunologic alterations affect the endothelial phospholipids. These effects promote the pathogenicity of otherwise harmless APL antibodies. Therefore hypercoagulability is unpredictable in APL syndrome. Likewise "healthy" people with APL antibodies could remain asymptomatic for many years.
Infection-related APL antibodies are usually transient and do not offer an increased risk for thrombotic events (1, 32) . The affinity of autoimmune APL antibodies for their protein antigens in the circulation is often at most moderate, which is also a characteristic of natural autoantibodies (125). Indeed, patients with antibodies against either β 2 GP-1 or prothrombin do usually have normal circulating levels of these proteins. Therefore, some other authors concluded that the origin of pathogenic autoimmune APL antibodies resides in deregulated overproduction of natural antibodies rather than in antigen-driven formation of immune antibodies (125).
APL Antibodies and Apoptosis
Anionic phospholipids are almost exclusively located in the intracellular surface of cell mem-branes, whereas cardiolipin is located primarily on the mitochondial membranes. Therefore, APL antibodies cannot react with their targets under normal conditions. Redistribution of the anionic phospholipids from the intracellular to the extracellular compartment can occur in certain physiologic conditions such as platelet activation or apoptosis (98, 126, 127) . Cardiolipin molecules were expressed on the surface of apoptotic cells and were recognized by APL antibodies (128). β 2 GP-1 bound selectively to the surface of apoptotic cells (57,127,129). The binding of β 2 GP-1 to the surface of the apoptotic cells generated an epitope for the binding of APL autoantibodies (127). Heterologous human β 2 GP-1 bound to the surface of apoptotic cells induced the production of ACAs and LA activity in non-autoimmune mice (130). Importantly, neither apoptotic cells nor β 2 GP-1 alone could be able to induce generation of ACAs after intravenous injection (130).
Subcutaneous or intradermal administration of the heterologous β 2 GP-1 molecule alone could also induce generation of APL antibodies (5, (117) (118) (119) . Slow absorption of the β 2 GP-1 over several days may induce such a phenomenon. During the sustained absorption time, β 2 GP-1 could bind to apoptotic cells of the host. This interaction could be induced by the generation of local inflammatory response secondary to co-administration of the adjuvant (namely CFA, complete Freund's adjuvant) (130). Therefore apoptotic cell-bound β 2 GP-1 appears to be a "true" immunogen for the production of APL antibodies. β 2 GP-1 complexed with native cardiolipin is structurally altered. Likewise, intravenous immunization of mice with β 2 GP-1 in the presence of cardiolipin vesicles induced a high level of anti-β 2 GP-1 antibodies, ACAs, and LA activity (131). On the other hand, binding of APL antibodies to apoptotic cells can occur in both in a β 2 GP-1-dependent and independent way (132). Taken together, these data provide evidence that exposure of phospholipids during apoptosis may be an early event in the apoptotic cellular program leading to specific interactions with circulating phospholipid-binding plasma proteins such as β 2 GP-1. The binding of the β 2 GP-1 molecule to those phospholipids exposed on the apoptotic cells could be immunogenic. That phenomenon can break tolerance and trigger the generation of APL antibodies. Once an immune response is initiated against such an immunodominant epitope, the immunologic response can expance to other epitopes within the complex by the process of epitope spreading. As "the end," the APL anti-body response eventually includes autoantibodies against β 2 GP-1 or phospholipids alone, or against a new epitope generated after the interaction between those molecules (130,131,133).
Role of Lipid Peroxidation in the Initiation and/or Propagation of APL Syndrome
Oxidative injury has been suggested in the pathogenesis of a variety of disorders including vasculitic syndromes and atherosclerosis. Likewise, a number of experiments provided evidence that oxidative damage could have a role in the pathobiology of the APL syndrome. Native cardiolipin, the naturally occurring form of cardiolipin, is highly susceptible to oxidation, particularly upon exposure to air. In contrast, hydrogenated cardiolipin is unable to undergo lipid peroxidation. Cardiolipin is highly sensitive to lipid peroxidation under conditions of solidphase immunoassay. Both sera and affinity purified ACA IgG from APL syndrome patients bound to oxidized cardiolipin, but did not bind to hydrogenated cardiolipin. These data suggest that APL antibodies are directed at neoepitopes generated when cardiolipin undergoes the process of peroxidation (134). Moreover, β 2 GP-1 was recognized by the APL sera only when bound to oxidized cardiolipin, but not when bound to the reduced cardiolipin analog unable to undergo oxidation (135). ACAs could bind to β 2 GP-1 only when it was bound to a microtiter plate that was previously irradiated, a condition that introduces oxygen radicals (9) . These data support the hypothesis that a simple phosholipid-β 2 GP-1 complex is not sufficient for the generation of APL antibodies unless the PL first undergoes oxidation. Therefore, many of the APL antibodies could actually be antibodies directed against oxidized phospholipids (134,135).
Oxidative stress is a potential component of the final common pathway leading to apoptosis. On the other hand, cells sustained progressive lipid peroxidation following an apoptotic signal (136,137). Therefore, the apoptotic cell surface is a site of increased oxidative activity. Immunogenicity of apoptotic cell-bound β 2 GP-1 depended upon prolonged interaction between β 2 GP-1 and the apoptotic cell surface (130). Hence both apoptosis and oxidative injury may play a dual role in the pathogenesis of APL antibodies.
Antiplatelet Antibodies in APL Syndrome
There is some evidence suggesting that APL autoantibodies can cross-react with platelets and can affect both their quantity and function.
Platelet activation induces the exposure of anionic phospholipids on the outer leaflet of the membrane (126,138). Both ACAs and LAs bound to thrombin activated, but not unactivated resting, platelets (139). The most likely binding site was phospholipids because there was no crossreactivity of these antibodies with GPIIb/IIIa (139). Likewise, β 2 GP-1 preferentially bound to activated platelets. Binding of ACAs to platelet surface is also β 2 GP-1-dependent (138,139). Moreover, some APL antibodies can induce platelet activation and aggregation (140-145). Urinary excretion of the platelet-derived thromboxane metabolite 11-dehydro-thromboxane B2 was significantly increased in patients with APL antibodies (140). Activated platelets were detected by flow cytometry in the majority of APL syndrome patients with neurologic involvement (146). In contrast, although APL antibodies did bind to activated platelets, they may fail to induce platelet activation (139,147). Therefore, the role of platelet activation in the pathobiology of thrombosis in APL syndrome is not universal. Platelets circulating in an "over-activation state" in APL syndrome could either be a "cause" or an "effect" of the thrombosis or vascular injury (148).
Specific anti-platelet antibodies directed against major platelet membrane glycoproteins were higher in APL syndrome patients with thrombocytopenia compared to patients with normal platelet counts (149,150). Those antiplatelet antibodies did not demonstrate cross-reactivity with ACAs (149). Therefore, anti-platelet antibodies could represent a distinct group of auto-antibodies other than APL antibodies. They could play a significant role in the thrombocytopenia observed in APL syndrome. However, whether binding of these anti-platelet antibodies may play a pathogenic role in thrombosis on the basis of hyperaggregability remains obscure.
Heparin-induced thrombocytopenia (HIT) and APL syndrome have similar clinical presentations. Enhanced platelet activation at the vascular wall and endothelial injury are similar in both HIT and APL. Deposition of the immune complexes on slightly activated platelets further induces cellular activation. Likewise, generation of microvesicles provides much larger phospholipid surface area and results in enhanced thrombin generation (125, 151, 152) . In a recent mild radical-induced injury model in hamsters, anti-β 2 GP-1 antibodies were mainly localized within the platelet thrombus. This observation suggests that after a slight endothelial damage (first hit), acti-vated platelets exposed negatively charged phospholipids, leading to deposition of APL antibody complexes perpetuating the platelet activation and thrombus growth (second hit) (125,153).
Mechanisms of Pregnancy Loss in APL Syndrome
Intervillous thrombosis, intravillous infarctions, and decidual vasculopathy disturbing placental circulation were proposed as the pathobiologic basis of recurrent miscarriages in women with APL syndrome (154,155). The previouslymentioned hypotheses regarding the prothrombotic state of APL syndrome could contribute to the placental thrombosis. The "disruption of the annexin V shield" hypothesis could offer a logical explanation for the placental thrombosis (69). Annexin V is normally located on the apical surface of syncytiotrophoblasts lining the placental villi (156,157). This protein is constitutively produced to maintain the fluidity of the intervillous circulation and consequently to maintain fetal viability (156,157). Infusion of anti-annexin V antibodies caused placental thrombosis, necrosis, and fetal loss in animal models (157). Interestingly the concentrations of this placental anticoagulant factor are markedly reduced on placental villi in APL patients with spontaneous recurrent abortion (158). Moreover, APL antibodies decreased the levels of villous surface annexin-V on placental villi (158,159). APL antibodies both reduced the levels of annexin V and also accelerated the coagulation of plasma on cultured trophoblasts and endothelial cells (69). Therefore, deficiency of placental surface annexin-V caused by APL antibodies may complicate the placental thrombosis observed in those patients (69,158). In contrast, ACA-β 2 GP-1 complexes failed to displace preadsorbed annexin V from lipid bilayers in another study (73). No difference was observed regarding the intensity of immunostaining for annexin V between placentas from women with APL syndrome and those from control subjects (160). Therefore, placental thrombosis cannot be solely attributed to the displacement of the annexin V shield, and other prothrombotic mechanisms could be operative as well.
On the other hand, placental infarction is not present in all the placentae of patients with APL syndrome. Furthermore, although placental thrombosis could be responsible for late fetal losses, early miscarriages cannot be explained by placental thrombosis (155,161). Recent reports have suggested that APL antibodies could induce trophoblast dysfunction such as decreased placental hormone production or trophoblast inva-sion. In a choriocarcinoma model of pregnancy, phosphatidylserine exposed during syncytium formation was targeted by APL antibodies. They inhibited the intercytotrophoblast fusion process and trophoblast invasiveness and secretion of human chorionic gonadotropin (159). APL antibody-containing sera suppressed human chorionic gonadotropin secretion by cultured trophoblast cells (162). Anti-annexin V antibody induced trophoblast apoptosis and significantly reduced trophoblast gonadotropin secretion (163). Moreover, β 2 GP-1-dependent APL antibodies as well as APL antibodies against the phospholipids themselves attacked the trophoblasts, and both groups of antibodies negatively affected trophoblast implantation and development (164). In this regard, APL antibodies can affect trophoblast gonadotropin secretion and invasiveness by binding directly to anionic phospholipids and through adhered β 2 GP-1. Alternatively they can induce apoptosis and lead to the defective placentation in APL syndrome (159, 163, 164) .
Establishment of the human placenta requires invasiveness of fetal cytotrophoblast stem cells in anchoring chorionic villi. Trophoblast invasiveness and differentiation are dependent on adherence to the extracellular matrix, response to external cytokine signals, and expression and the alteration of adhesion proteins. During normal cytotrophoblast differentiation along the invasive pathway, the differentiating cytotrophoblasts dramatically transform their adhesion receptor phenotype. These data suggest that a unique adhesion phenotype switch is required for the successful endovascular invasion and normal placentation (165,166). The effects of APL antibodies on trophoblast adhesion molecules (alpha1 and alpha5 integrins, E-and VE-cadherins) were investigated in primary cytotrophoblast cell cultures. APL antibodies modulated the trophoblast cadherins repertoire in vitro, suggesting that recurrent pregnancy loss in APL syndrome could be associated with abnormal cytotrophoblast expression of adhesion molecules (167).
The Role of Genetic Predisposition in APL Syndrome
Familial clustering of increased APL antibody levels has been described (168). Moreover, certain polymorphisms of the β 2 GP-1 molecule were associated with the presence of anti-β 2 GP-1 antibodies and APL syndrome (169,170). Associations with HLA DR4, DR5, and HLA-DQ7 antigens and primary APL syndrome were reported (171-174). Frequency of HLA-DR7 was in-creased in SLE patients with ACAs (173,175). However, those studies were carried out in a limited number of patients and genetic marker(s) for APL syndrome have not yet been demonstrated in large cohorts of subjects from different ethnic populations.
Other Thrombophilic Triggers Complicating the Genesis of APL Syndrome
The fibrin polymerization rate is increased in patients with APL syndrome (176). Fibrinolytic activity could be suppressed by APL antibodies. Impaired fibrinolysis could be either due to the increments in PAI-1 activity or to the inhibition of factor XII activation together with the inhibition of XIIa (177,178). APL antibodies also inhibit heparin-accelerated formation of antithrombin III-thrombin complexes (179).
In conclusion, for the thrombophilia mechanism of APL syndrome, several different and/or related pathogenic mechanisms could be operative concurrently, and even in the same patients to induce the generation of the features of APL antibodies. Each of the previously mentioned mechanisms could be in part operative during the pathobiologic course of APL syndrome. Moreover, it is likely that those mechanisms are tightly integrated and can display complex dual interactions as a vicious cycle. For instance, while apoptosis induces generation of APL antibodies, LAs can trigger endothelial cell apoptosis. Apoptosis is able to induce oxidative damage. Oxidative damage is a well-known inducer for apoptosis. APL antibodies can induce pathologic activation and/or injury to platelets and endothelium. The activation of those cells causes exposure of anionic phospholipids that can secondarily amplify the generation of APL antibodies. Therefore, complex interactions of biologic structures and molecules are operative in the genesis of APL syndrome. A list of proposed mechanisms in the pathobiology of APL syndrome is given in Table 1 .
LABORATORY DIAGNOSIS OF THE ANTIBODIES IN THE APL SYNDROME
The laboratory diagnosis of APL syndrome depends on the detection of autoantibodies directed against anionic phospholipids and/or a variety of phospholipid binding proteins. Solid-phase immunoassays and phospholipid-dependent tests of hemostasis are used for this purpose (21,67,180-182). There still remain some problems in the detection, standardization, clinical utility, relevance, and significance in the laboratory diagnosis of APL syndrome. 
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Solid-Phase Tests of APL Syndrome-Associated Antibodies Solid-phase tests are developed and widely used to detect antibodies against β 2 GP-1 (antiβ 2 GP-1), cardiolipin (ACA), prothrombin, annexin V, phosphatidylserine, phosphatidyletanolamine, and many others of which their numbers are growing (180,183). Therefore, more specific measurements of antibodies associated with APL syndrome are currently available via solid-phase assays (180). A detailed summary regarding the current knowledge and clinical applications of novel antigenic targets in APL syndrome is given in "Heterogeneous clinical and laboratory manifestations of the patient(s) with APL syndrome: a logical approach for the use of various APL antibodies" section of this review. Nevertheless, there are many complicated problems restricting the predictive ability of current diagnostic tests in terms of the lack of standardization, reproducibility, and lack of prospective and multivariate epidemiologic analysis (21). The inter-laboratory coefficient of variation for IgG APL units was found to be higher than 70%, though the within-run coefficient of variation had a median value of 10% in the First French Anticardiolipin Antibodies Standardization Workshop (184) . ACA assay is currently a "routine" standard in the diagnosis of APL syndrome. However, critical laboratory tests should be repeated at least once before reaching a clinical decision in APL syndrome (185) . Another study focusing on ACA assay usefulness suggested "exceedingly high interlaboratory result variation, combined with a general lack of test result grading consensus and method-based variation" (185) . In that study, cross-laboratory testing of samples yielded interlaboratory coefficients of variation for lgG ACA and IgM ACA that were higher than 50% in cases. General consensus (interlaboratory agreement, 90% or more) was obtained in approximately 40% of cases only. Different laboratories usually failed to agree on whether a sample was ACA-positive or ACA-negative. Distinct methods in various laboratories tended toward higher or lower ACA values (185) . Hence, the laboratory data obtained by ACA assays should be interpreted together with the clinical presentation of the patients, as discussed in various sections of this review.
Phospholipid-Dependent Hemostatic Tests of APL Syndrome-Associated Antibodies
The term LAs denotes some of the APL antibodies that prolong phospholipid-dependent clot-ting reactions in vitro. The main critical function of hemostasis laboratory in the diagnosis of APL syndrome is to measure LA. Essentially, a phospholipid-dependent screening assay such as activated partial thromboplastin time (aPTT) is performed to test LA. If this screening test is prolonged, normal plasma is added to the tested sample in a 1:1 mixture. If the LA is present, addition of normal plasma does not correct the prolonged assay. The next step for LA detection is to add excess phospholipid to the tested sample. Naturally, addition of those phospholipids does correct the prolonged assay. In cases of coagulation factor deficiency, addition of normal plasma corrects the prolonged assay at the second step of the experiment. In the presence of anti-coagulation factor inhibitors, prolonged assay is never corrected in all steps of the tests. Specific measurements of anti-factor inhibitors are mandatory for the diagnosis of those cases ( Fig. 2) (186) . The sensitivity of numerous screening or confirmatory assays for the diagnosis of LA may vary.
Attention to the ratio of tested patient plasma to normal plasma is important to detect a circulating inhibitor especially in a minimally prolonged aPTT. Furthermore, the normal plasma source must be "platelet poor" to maximize sensitivity in the case of a weak LA (187) . Dilute Russell viper venom time (dRVVT) is an important confirmatory test for the LA. Russell viper venom directly activates factor X. Therefore, dRVVT is not affected from the intrinsic factor deficiencies because they are bypassed. Thus, dRVVT is more sensitive than prolonged aPTT for the detection of LA (188) with varying reference ranges (189) . The sensitivity and specificity of commercial reagents for the detection of LA may exhibit marked differences in distinct coagulometers (190) . Several tests are developed for the diagnosis of LA, including platelet neutralization procedures (191) , platelet-derived microvesiclebased tests (192) , Textarin/Ecarin ratio (193) , hexagonal phase phospholipid neutralization assay (194) , silica clotting time (195) , kaolin clotting time (196) , tissue thromboplastin inhibition test (197) , dilute prothrombin time-based lupus ratio test (198) , Taipan snake venom time (199) , and lupus ratio test, a mixture of a lupussensitive and a lupus-insensitive aPTT-reagent with normal plasma (200) . The use of platelets in confirmatory tests may lead to false-positive results especially in anti-factor V and heparin-like inhibitors (201) .
A normal aPTT result does not exclude the presence of LA. In approximately half of APL syn-drome cases, aPTT is prolonged. LA testing, on the other hand, is the most difficult task in the everyday practice of the hemostasis laboratory. Not only the enigmatic clinical course of the APL syndrome, but also certain technical issues complicate the detection of LA (201) . Contamination with platelets, instrumental effects, pH drift during incubation, and difficulties in standardization represent some of the problems for LA laboratory identification (201) . Anti-β 2 GP-1 and anti-prothrombin monoclonal antibodies offered better understanding of the mechanism by which LA prolongs in vitro clotting. LA-positive monoclonal antibodies also improved the LA diagnosis (67). Mixing studies are widely used to identify LA or any other circulating coagulation inhibitor (187) . There are some important variables in case of "mixing." The normal plasma source should be platelet-poor to maximize sensitivity as mentioned previously. The patient plasma to normal plasma ratio is extremely important, particularly in the suspected APL syndrome case of a minimally prolonged aPTT (187) . A hemostatic test should be optimally combined for the detection of LA or exclusion of a coagulation inhibitor. Twenty-one patients who initially presented with a prolonged prothrombin time (PT) or aPTT or both were tested for the presence of LA in a study (202) . The authors used a battery of coagulation tests, including both immediate and 2-hour mixing studies, a platelet neutralization procedure, a tissue thromboplastin inhibition test, and dRVVT. Ten percent of the patients only had a prolonged PT, 33% only had a prolonged aPTT, and in 57% both test results were abnormal. In 15 patients, inhibition was evident on immediate assay of equal-volume mixture studies of patient plasma and normal pooled plasma. However, in some patients, it was evident only after a 2-hour incubation period. Therefore, proper incubation is important in mixing studies for LA or inhibitor detection. Fifteen of 18 samples showed correction of the abnormal screening study when platelets were used as a source of phospholipid.
Both the tissue thromboplastin inhibition (abnormal in 20 of 21 samples) test and dRVVT (in 13 of 14 samples) were found to be sensitive assays (202) . The dRVVT test correlates most closely with elevated anticardiolipin antibodies. A heterogeneous cohort of 725 patients referred for LA detection was reviewed in a retrospective study (203) . A positive LA test result was defined by abnormal results obtained by at least two techniques from the reagents used and confirmed with a platelet-neutralizing procedure. The authors found that a positive dRVVT test result is strongly correlated with elevated ACA (203) . Sakakura and coworkers investigated kaolin clotting time, mixing with normal plasma in kaolin clotting time, dRVVT, dRVVT at high lipid concentrations, APL antibodies, and ACA-β 2 GP-1 complex antibody in 135 patients with prolongation of aPTT and diagnosed 86 patients positive for LA. In this study, the sensitivity of aPTT and dRVVT/dRVVT-high lipid concentrations ratio for LA was markedly high, but the specificity of aPTT for LA was not so remarkable. The specificity, but not the sensitivity, of kaolin clotting time mixing with normal plasma in kaolin clotting time was also markedly high. The authors concluded that dRVVT/dRVVT-high lipid concentrations ratio gave high sensitivity as well as specificity. Of their patients positive for LA, 25% were found to be positive for APL antibodies and 17% were positive for ACA-β 2 GP-1 complex antibody (204) .
Clinical strategy is important for the selection of laboratory tests for the detection of LA (205, 206) . A decision tree can be constructed using a combination of aPTT and dRVVT with confirmatory tests, tissue thromboplastin time (TTI), platelet neutralization procedures, and mixing studies (205) . Predictive values (207) and clinical associations (208, 209) of all laboratory tests may vary. Optimization of solid-phase and hemostatic tests should be performed for the rational approach to the management of APL syndrome (210, 211) .
CLINICAL FEATURES OF THE APL SYNDROME
Thrombosis is the basic pathologic process in the APL syndrome. It represents the main mechanism behind the majority of the clinical features in patients with APL syndrome. Arterial and venous thrombosis can be present in APL syndrome. Any organ system and any size of vessel can be affected during the clinical course of the disease. Therefore, the spectrum of clinical findings is extremely wide (Fig. 3) .
In terms of overall frequency, a recent multicenter study of a cohort of 1000 patients with APL syndrome demonstrated that the most common initial manifestations were deep vein thrombosis (31.7%), thrombocytopenia (21.9%), livedo reticularis (20.4%), stroke (13.1%), superficial thrombophlebitis (9.1%), pulmonary embolism (9.0%), fetal loss (8.3%), transient ischemic attack (7.0%), and hemolytic anemia (6.6%) (23). The frequencies of the majority of clinical features including recurrent thromboses and miscarriages are comparable in primary and secondary APL syndromes. However, arthritis, livedo reticularis, thrombocytopenia, and leukopenia appear to be more common in SLE-associated APL syndrome (23). Those differences could probably be attributed to the association of the manifestations with SLE itself. Likewise, the female-to-male ratio was higher in the SLE-APL syndrome group (23).
Venous Thrombosis in APL Syndrome
Venous thrombosis most commonly involves deep and superficial venous system of the legs. Venous involvement often takes place as bilateral and multiple (23). Deep venous thrombosis can be resulted in pulmonary thromboembolism in up to one third to half of APL syndrome patients (1, 23) . Other less commonly involved sites of venous thrombosis include adrenal, hepatic, mesenteric, portal, splenic, subclavian, jugular, retinal, renal, skin, or upper extremity veins; superior and inferior vena cavae; and cerebral venous sinuses (1, 23) . The presenting symptoms depend on the localization, extent, and acuity of the thrombosis. Thrombosis can occur spontaneously. However, the presence of a precipitating factor such as hormone replacement therapy, oral contraceptives, immobilization, trauma, congestive heart failure, or pregnancy increases the risk of thrombosis (1) .
Neurologic Features in APL Syndrome
Recurrent stroke and transient ischemic attacks are the most common neurologic manifestations of APL syndrome (23, 29, 212, 213) . Arterial thrombotic events and embolism from cardiac vegetations may represent the underlying mechanism (1) . Ischemic events can occur in any vascular territory of the brain. The average age of onset of an APL-associated cerebrovascular event is approximately a decade younger than that of the typical cerebral ischemia population (45). Some cases may lead to multiinfarct dementia. Other stroke risk factors such as cigarette smoking or hyperlipidemia may further complicate the risk of recurrent ischemic events in patients with APL syndrome (29). A less common cerebral vascular thrombotic manifestation was cerebral sinus thrombosis (1, 23, (212) (213) (214) . Other less common neurologic manifestations of APL syndrome are migraine-type headache, chorea, transverse myelopathy, myasthenia gravis, Guillain Barré syndrome, transient global amnesia, seizures, motor neuron disease, and depression. However their associations with APL syndrome have been less well-determined (29, [212] [213] [214] . Cerebral dysfunction in APL syndrome may range from mild cognitive dysfunction to severe dementia. Retinal and choroidal vessel involvement may cause acute ocular ischemia and transient blurred vision or amaurosis fugax, transient diplopia, and decreased vision. Transient field loss may also develop (1, 29, (212) (213) (214) (215) (216) . Sudden sensorineural hearing loss has been rarely reported in APL syndrome (217) .
Cardiac Features in APL Syndrome
The most common cardiac manifestation of APL syndrome is valvular pathologies. They include verrucous endocarditis, valvular thickening, and insufficiency. Valvular stenosis is rarely seen. The mitral valve is the most commonly affected site, followed by the aortic valve, although the tricuspid or pulmonary valve can also be affected (1, 23, 214, (218) (219) (220) . A strong association between valvular abnormalities and arterial brain infarcts in APL syndrome patients does exist. This association reflects the embolization from the damaged valve (219) . Patients with APL syndrome have increased risk for myocardial infarction, increased risk for graft occlusion after coronary artery bypass surgery, and restenosis after angioplasty (18, 26, 214, 221) . APL antibodies may rarely cause myocardial infarction even in the presence of normal coronary arteries (222) . In addition, there have been some reports of intracardiac thrombi or cardiomyopathy in association with the APL syndrome (23,218). 
Cutaneous Lesions in APL Syndrome
Cutaneous lesions appear in approximately one third of patients with APL syndrome. Livedo reticularis is by far the most common cutaneous manifestation. It is frequently the initial clinical feature of the syndrome (23,223). Other cutaneous findings of the APL syndrome include necrotizing vasculitis, livedoid vasculitis, thrombophlebitis, cutaneous ulceration, necrosis, erythematous macules, purpura, ecchymoses, painful skin nodules, and subungual splinter hemorrhages (214, 223) .
Pulmonary Involvement in APL Syndrome
The most common pulmonary complications of APL syndrome are pulmonary thromboembolism and pulmonary hypertension (23, 214, 224) . Pulmonary embolism occurs in approximately 14% to 30% of the patients. It may be the initial feature in approximately 9% of the patients (23,214). Thrombosis in calf veins, inferior vena cava, tricuspid valve vegetations, and right-sided intracardiac thrombosis may be the source of pulmonary emboli (214) . Recurrent pulmonary embolism may lead to thromboembolic pulmonary hypertension. Severe cases with pulmonary hypertension may be accompanied by isolated tricuspid valve insufficiency (224) . Several cases of "primary" (non-thromboembolic) pulmonary hypertension complicating primary APL syndrome have been described. The outcome in patients with pulmonary hypertension and APL syndrome is usually fatal (224) . Rare cases with diffuse alveolar hemorrhage, fibrosing alveolitis, adult respiratory distress syndrome, and pulmonary artery thrombosis have all been reported (23, 214, 224) .
Renal Involvement in APL Syndrome
Renal manifestations of the APL syndrome are relatively rare, occurring in 2.7% of all cases (23). Vasoocclusive events can occur at any level of the renal vasculature. The disease may affect the main renal artery and its branches, arterioles, glomerular capillaries, and renal veins. Characteristic histologic findings of renal APL syndrome are intrarenal vascular lesions, arteriosclerosis, fibrous intimal hyperplasia, partial or complete vascular occlusions, and thrombotic microangiopathy. Focal cortical atrophy is another finding. Inflammatory vascular lesions are typically absent (225) . These histopathologic findings are clinically manifested by hypertension, acute or chronic renal insufficiency, proteinuria, nephrotic syndrome, and inconsistent hematuria in the majority of the APL syndrome patients (1, 214, 225, 226) . Among those manifestations, hypertension is of particular importance because it is almost invariably present among patients with renal APL syndrome (225) . Mild, severe, or even malignant hypertension may be present. All patients with APL syndrome and hypertension should be investigated for renal involvement (especially renal artery stenosis). Hypertension is often the only early clinical manifestation of renal APL syndrome. Other nephrologic manifestations of APL syndrome include hemodialysis vascular access thrombosis, and primary graft non-function in renal transplant recipients (214, 226) .
Hematologic Manifestations in APL Syndrome
Thrombocytopenia in the APL syndrome is a frequent finding, occurring in 20% to 30% of patients (23,214). It is usually chronic and mild, and does not cause a severe bleeding complication (23,214). On the other hand, elevated levels of APL antibodies are common in immune thrombocytopenic purpura, and the persistent presence of APL antibodies is an important risk for the development of thrombosis or fetal loss (227) .
Autoimmune hemolytic anemia may develop in some patients with APL syndrome. The direct Coombs' test result is positive in 14% of patients with primary APL syndrome and 40% of patients with APL syndrome secondary to SLE. However, hemolytic anemia is not common in those patients (214) . Autoimmune hemolytic anemia is more common in secondary APL syndrome (23). DIC, hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura are uncommon complications of APL syndrome. However, they represent the drastic rare clinical manifestation called catastrophic APL syndrome (1) .
Other Manifestations of APL Syndrome
Nasal septum perforation, pancreas infarction, splenic infarction, Budd-Chiari syndrome, Addison's disease due to adrenal infarction, and pituitary failure after necrosis of the pituitary gland have all been reported in APL syndrome (1, 23, 228) . Musculoskeletal manifestations including arthralgia or arthritis are very common (38.7% and 27.1%, respectively) (23). Avascular necrosis of bone may occur in approximately 2% of the patients (23). However, this necrotic complication can be detected by magnetic resonance imaging in approximately one fifth of the patients with primary APL syndrome who did not receive steroids before (229) .
Obstetric Complications in APL Syndrome
APL syndrome is associated with both fetal and maternal complications. Fetal complications include both early abortions before the 10th week of gestation and fetal deaths at or after the 10th week of gestation. Preterm labor at or before the 34th week of gestation may also take place (1, 230) . These obstetric features were specifically mentioned in the 1999 International Consensus Statement Classification Criteria for APL syndrome (231) . Other obstetric complications include intrauterine growth retardation, placental abruption, pre-eclampsia, and eclampsia (1, 23, 226, 230) . Association with HELLP syndrome (hemolytic anemia, elevated liver enzymes, low platelet count in association with preeclampsia) has been rarely reported (1) .
Catastrophic APL Syndrome
Catastrophic APL syndrome is an acute and drastic manifestation of the APL syndrome characterized by clinical involvement of at least three different organ systems over days or weeks with histopathologic evidence of multiple occlusions of large or small vessels (232) . It is fortunately a rare complication (less than 1% of all patients with APL syndrome). The mortality is as high as 50% and most patients die as a result of a combined cardiac and respiratory failure (232, 233) . Respiratory failure can develop after acute respiratory distress syndrome (ARDS) and diffuse alveolar hemorrhage. Precipitating factors include infections, trauma, surgery, drug administration, and warfarin withdrawal in 22% of the patients with catastrophic APL syndrome. The majority of those patients develop widespread vascular occlusion mainly affecting small vessels of organs, particularly kidney, lungs, brain, heart, adrenal glands, and liver, causing microangiopathy. Only a minority of these patients experience occlusion of a single large vessel. Digital ischemia with frank gangrene, superficial skin necrosis, and ischemic ulceration of the limbs may develop. Thrombocytopenia was reported in 68% of the patients, hemolytic anemia in 26%, and DIC in 28%. They all have the potential to contribute to the multiorgan thrombotic microangiopathy in catastrophic APL syndrome (232, 233) .
HETEROGENEOUS CLINICAL AND LABORATORY MANIFESTATIONS OF THE PATIENT(S) WITH APL SYNDROME: A LOGICAL APPROACH FOR THE USE OF VARIOUS APL ANTIBODIES
The spectrum of antigens and autoantibodies in the APL syndrome is expanding. Conventional approach for the detection of APL antibodies includes the clotting-based assay LA and solid phase immunoassays for ACAs. However, a significant number of patients with clinical features of APL syndrome remain negative for those conventional APL assays. Hence, tremendous efforts are being spent to demonstrate novel antigenic targets and to develop novel laboratory assays to improve the diagnostic yield in the APL syndrome. However, those efforts in the laboratory may adversely affect critical clinical decision making in the clinic. Therefore, a hierarchical and rational approach is necessary for effective clinical management of APL syndrome patients.
Since the first documentation in 1983 (234), a large number of clinical studies documented the association between the ACAs and the development of arterial and/or venous thrombotic events (40-43, [235] [236] [237] . ACAs can also significantly increase the recurrence risk following an episode of vascular thrombosis (25, 238, 239) . The risk for development of APL antibody-related disorders is higher in patients with high titer IgG isotype (40, 41, 44, 45, 240, 241) . However, IgM isotypes and low titer ACAs could be associated with an increased thrombosis risk as well (236, 237) . Moreover, there is growing evidence for the association of IgA isotype ACAs and APL antibody-related disorders (242, 243) . It is generally, however, not assayed routinely and not suggested as a diagnostic criterion because other authors failed to confirm this association (244) (245) (246) .
The association of ACAs with vascular thrombosis is not, however, universally confirmed (15, 46, 241, (246) (247) (248) . A recent meta-analysis concluded that only high-titer IgG isotype ACA is clearly associated with thrombosis. Less consistent results are available for IgM isotype ACAs and low titer IgG isotype ACAs (241) . However, there are significant differences between those studies regarding the methods of the research, associated clinical conditions, clinical end-points, laboratory methods for the detection of ACAs, and cut-off levels for the antibodies. Thus, the comparison of studies is really problematic. The titers for APL antibodies can fluctuate. Furthermore patients who had initially had negative test results for APL antibodies could have positive test results for ACAs later (20,249). Therefore, prospective well-designed studies via serial measurements of ACAs with better interlaboratory harmonization at certain critical time points during the clinical course of APA syndrome is strictly needed to draw more dependable conclusions. However, in everyday clinical practice, ACA IgG, IgM, and IgA antibodies should be searched in cases of unexplained arterial and/or venous thrombosis (18, 26, 28, 250) .
The association of LAs and thrombosis is more significant. The risk of thrombosis is independent of the laboratory tests used to identify the LAs (46, 235, 241, [251] [252] [253] [254] . LAs are more closely associated with arterial and/or venous thrombosis than ACA antibodies (235, 241, 253, 254) . Patients with SLE and LA are at approximately six times greater risk for venous thrombosis than patients without LA. On the other hand, patients with SLE and ACA antibodies have an approximate two times greater risk for venous thrombosis than patients without ACA antibodies (254) . A recent meta-analysis examining the risk of venous thrombosis in individuals with APA syndrome without underlying autoimmune disease or previous thrombosis revealed that the risk for thrombosis is higher in patients with LA than in other patients. This risk was also higher than in patients with ACAS even when only high titers were considered (253) .
The closer association of the LAs with thrombosis could be partly attributed to the lower sensitivity and greater specificity of LA versus ACA assays (235, 250) . ACA ELISA is more sensitive but less specific than the LA assay (235, 250) . In the cohort of 1000 well-documented patients with APL syndrome, the presence of ACA was detected in 879 patients and LA in 536 patients (23). Therefore, any test is neither sufficiently sensitive nor specific for screening or diagnostic purposes. Both tests should be assayed and repeated in cases of strong suspicion for APL syndrome (18,26,28).
The presence of β 2 GP-1-independent benign ACAs in the general population naturally decreases the specificity of the ACA assay for the diagnosis of APL antibody syndrome. The antibodies against β 2 GP-1 are directed to an epitope readily available on the native protein (255) . Tests specific for β 2 GP-1 can help to distinguish false positive biologic test results for syphylis and true APL antibodies (256) . There is a subgroup of patients who demonstrate clinical features compatible with APL antibody syndrome but are negative for conventional APL antibody assays (17, 257) . Therefore, antibodies against the β 2 GP-1 molecule detected with solid phase ELISA could improve the specificity of conventional APL antibody assays for the diagnosis of APL antibody syndrome. Anti-β 2 GP-1 antibodies may even be superior to ACA assays for the diagnosis of APL antibody syndrome based on some studies (22, [258] [259] [260] [261] [262] . Some other studies suggested that anti-β 2 GP-1 ELISA does not give additional information for a thrombotic risk than the conventional APL antibody assays (235, (263) (264) (265) (266) . A recent meta-analysis concluded that firm evidence for the association of anti-β 2 GP-1 antibodies and thrombosis is still lacking (267) . Likewise, the anti-β 2 GP-1 antibodies are not more sensitive than conventional APL antibody assays for the diagnosis of APL syndrome in women with recurrent fetal loss (211, (268) (269) (270) . A potential advantage of screening for anti-β 2 GP-1 antibodies could be increasing the specificity and the positive predictive value of the ACA testing in ACA-positive patients (211, 271) . Moreover, the presence of anti-β 2 GP-1 antibodies in patients with LA and high titer ACAs could also be of prognostic importance and should alert the physician about the risk for the bad outcome of the disease (264) . However, the antiβ 2 GP-1 assay is not recommended for a "first-line" screening test in suspected cases for APL antibody syndrome. It could be searched if both LA and ACA remained negative and still suspicion persists (18,21,26,28,250,264).
Prothrombin is another major phospholipid binding protein. The prevalence of anti-prothrombin antibodies ranges from 50% to 90% in APL antibody-positive patients depending on the laboratory methodology (272) . Antibodies against prothrombin were demonstrated in patients with LAs and severe hypoprothrombinemia or in patients with LAs and normal prothrombin levels (273) (274) (275) . Anti-prothrombin antibodies are associated with LA activity (4, 250) . They can also be determined by standard ELISA method (276) . A number of clinical studies evaluated the presence of anti-prothrombin antibodies as a risk factor for arterial and/or venous thrombosis in APL syndrome. Some authors reported significant correlation with anti-prothrombin antibodies and thrombosis (277) (278) (279) (280) (281) (282) , while some others did not (235, (283) (284) (285) (286) . Therefore, routine measurement of anti-prothrombin antibodies is not recommended to define their thrombotic risk in patients with APL syndrome (68, 267, 272) . Antiprothrombin antibodies do not interfere with the coagulant properties of prothrombin (68). Moreover, most of them may react with neoepitopes generated after the binding of the prothrombin molecule to phosphatidylserine via calcium ions (68). The anti-prothrombin antibodies detected in those previously mentioned assays were directed against the prothrombin molecule alone. Antibodies against phosphatidylserine-prothrombin complex were more closely associated with LA activity than the anti-prothrombin antibodies. They are significantly correlated with the clinical manifestations of the APL syndrome while anti-prothrombin antibodies were not (287, 288) . Therefore the place of anti-phosphatidylserineprthrombin complex antibodies as a marker for APL syndrome remains to be elucidated.
Annexin V is a tissue and circulating phospholipid-binding protein with anticoagulant properties. It has high affinity for anionic phospholipids and can displace coagulation factors from phospholipid surfaces (38). Displacement of the annexin V shield by APL antibodies has been proposed in the pathogenesis of APL syndrome as discussed previously (38). Antibodies directed against the annexin V molecule do have LA properties (289) . Anti-annexin V antibodies have also been reported in some patients with APL syndrome (277, 290, 291) . Moreover anti-prothrombin and anti-annexin V antibodies could be more specific for the diagnosis of APA syndrome (277) . Furthermore, anti-annexin V IgG antibodies were associated with higher incidences of arterial or venous thrombosis, intrauterine fetal loss, and prolonged aPTT in patients with SLE (292). However, conflicting data exist regarding the association of anti-annexin V antibodies and the clinical manifestations of the APL syndrome (291) . Hence, strong evidence for the functional and clinical significance of those autoantibodies is not yet available.
Low density lipoprotein (LDL) oxidation may contribute to the development of atherosclerosis in vivo (293, 294) . Oxidized LDL is more immunogenic, and led to the generation of autoantibodies (295) . Antibodies directed against oxidized LDL were associated with myocardial infarction in prospective studies (296) . Circulating LDL contains significant amounts of cardiolipin suggesting that many ACAs and anti-oxidized LDL antibodies may be directed at similar epitopes (297) . Moreover, APL antibodies are crossreactive to oxidized LDL (298) . On the other hand, anti-oxidized LDL antibodies are higher in patients with APL syndrome compared to healthy controls and patients with SLE without clinical features of APL syndrome (299) (300) (301) . The levels of anti-oxidized LDL did not show strong correlation with those of anti-β 2 GP-1 or ACAs. Therefore anti-oxidized LDL may represent a distinct subset of antibodies (299) . Elevated levels of anti-oxidized LDL antibodies are potential markers for the development of arterial thrombosis in patients with APL syndrome (299, 300) . However, following studies failed to demonstrate an association between high anti-oxidized LDL antibody levels and arterial thrombosis (301, 302) . On the contrary, high anti-oxidized LDL antibody titer was correlated with venous thrombosis in another study (301) . Moreover, the association of anti-oxidized LDL antibodies and primary APL syndrome also remains controversial (301) . Therefore, additional studies are needed to determine the exact clinical relevance of anti-oxidized LDL antibodies in the APL syndrome.
Pathologic activation of the endothelial cells by APL antibodies contributes to the prothrombotic state in APL syndrome as discussed previously. APL antibodies themselves bind to endothelial cells (100, 303, 304) . Moreover, a distinct group of endothelial cell reactive antibodies other than well-known APL antibodies can occur in the plasma of patients with APL antibodies (305, 306) . However, whether those antibodies are initiators of the endothelial injury or endothelial cell surface alterations lead to the formation of those antibodies remains to be elucidated. Although the presence of those anti-endothelial antibodies was associated with a history of thrombotic events (306) , the utility of the anti-endothelial cell antibodies in the diagnostic workup of the APL syndrome remains to be elucidated.
There are additional potential targets for APL antibodies, including protein C and protein S, thrombomodulin, factor XI, factor XII, high-molecular-weight kininogen, low-molecular-weight kininogen, tissue plasminogen activator, complement component C4, complement factor H, coagulation factor VII/VIIa, antimitochondrial antibody type 5, platelet-activating factor, and malondialdehyde-modified lipoprotein(a) (88-90, 283,307-315). However, the association of those auto-antibodies and APL syndrome has not been confirmed. Accordingly a firm evidence for the clinical use of those antibodies for investigating the APL syndrome is currently absent.
Cardiolipin is the most widely used phospholipid in the APL antibody assays. There is extensive cross reactivity between ACAs and antibodies against other phospholipids (316) (317) (318) . Therefore, serum anti-noncardiolipin antibodies could be identified by their cross-reactivity with ACAs. There may be no rational to perform ELISAs for other phospholipids. However, some of the antibodies against phospholipids other than cardiolipin cannot be detected by conventional ACA assays. ELISA methods based on cardiolipin as target antigen may not be sensitive enough to detect all APL antibody-positive sub-jects (19, 316, [319] [320] [321] [322] [323] . Moreover, a significant correlation was found between those antibodies and thrombosis and thrombocytopenia (321, 324, 325) . Recently, a multitarget ELISA assay using a coating mixture of cardiolipin and non-cardiolipin phospholipids including phosphatidylinositol, phosphatidylserine, and phosphatidylethanolamine was suggested to enhance the ability to identify patients with APL syndrome (316) . On the contrary, testing for APL antibodies other than LA and ACA is not clinically useful in the evaluation of APL syndrome (317, 326) . However, some patients with clinical features for APL syndrome who are negative for conventional APA assays (ACA and/or LA assays) can be positive for antibodies againts non-cardiolipin phospholipids (316, (319) (320) (321) (322) (323) . Therefore, patients whose clinical symptoms suggest APL syndrome but whose sera are negative for conventional APA assays should be screened for antibodies against non-cardiolipin phospholipids including phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, and phosphatidylcholine (18,26,28).
In summary, in a patient with unexplained thrombosis of any type or recurrent fetal loss both LA and ACA, all three assays should be performed. There is general agreement that solidphase ELISA is the method of choice for the detection of ACAs (18,26,28,327). For the detection of LAs, dRVVT seems to be the most sensitive assay (18,26,28). The titers for APL antibodies can fluctuate and patients who had initially had negative test results for LAs or ACAs could be later positive, or patients who initially had either IgM or low IgG can develop higher levels of IgG or LAs (20, 240, 249) . Therefore, patients should be re-tested for those assays in case of strong suspicion (21). For the patients with high suspicion for APA syndrome who disclose negative results for LA and ACA assays, the presence of isolated subgroup antibodies against β 2 GP-1, prothrombin, annexin-V, phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, or phosphatidylcholine should be tested (18,21,26,28,250).
THE "BICK CLASSIFICATION" OF APL ANTIBODY-MEDIATED THROMBOSIS SYNDROMES
Bick has proposed to divide the APL antibody-mediated thrombosis syndromes into six subgroups (18,26-28) ( Table 2 ). He stated that there is little overlap (approximately 10% or less) among these subtypes. Moreover, type IV patients (mixtures of types I, II, and III) are also uncommon, with most patients fitting into one of the first three types. This classification could be important for choosing the initial and longterm therapeutic alternatives from the clinical point of view. Recommended antithrombotic therapy regimens for each subgroup is given in Table 2 and also discussed in "Clinical strategies against APL syndrome" section.
DIAGNOSTIC CRITERIA OF APL SYNDROME:
A STILL ONGOING PROCESS
The diversity of the clinical and laboratory features of the APL syndrome necessitated a set of criteria for diagnosis. Preliminary classification criteria for APL syndrome were formulated during a post-conference workshop held in Sapporo in 1998 following the Eighth International Multidisiplinary Symposium on APL Antibodies (231) ( Table 3 ). The workshop focused on defining a category of "definite" APL syndrome. These criteria were intended to provide a uniform basis for clinical and research studies. The intention was not to guide clinical diagnosis or treatment of APL syndrome in individual patients. Therefore, the criteria encompass those clinical and laboratory features that were most closely associated with the APL syndrome in prospective clinical and experimental studies. IgG and IgM aCL antibodies can be detected in approximately 5% of normal subjects, while persistently elevated levels can be present in less than 2% on repeat testing (328) . Hence, the persistent presence of APL antibodies for 6 or more weeks is an essential requirement for APL syndrome classification. Other features of APL syndrome such as thrombocytopenia, hemolytic anemia, transient cerebral ischemia, transverse myelopathy, livedo reticularis, cardiac valve disease, multiple sclerosis-like syndrome, chorea, and migrane was not included in the Sapporo criteria because their associations were not strongly confirmed by clinical and experimental investigations. Likewise, anti-β 2 GP-1 antibodies, low-positive titers of IgG or IgM ACAs, IgA isotype of ACA, and antibodies against other phospholipids or phospholipidbinding proteins were not included as criteria in this classification (231, 329) .
Recently, the Sapporo criteria for APL syndrome were tested by experienced clinicians. Two hundred forty-three consecutive patients who had clinical diagnoses of primary APL syndrome (n=49), secondary APL syndrome (n=26), systemic lupus erythematosus (SLE) without clinical APL syndrome (n=131), and lupus-like disease without clinical APL syndrome (n=37) were classified according to the classification criteria. Sensitivity, specificity, positive predictive value, and negative predictive value were found to be 0.71, 0.98, 0.95, and 0.88, re-spectively (330) . Specificity and positive predictive value were high and these preliminary criteria could be useful for clinical studies. Sensitivity and negative predictive value were lower compared with physician-diagnosed APL syndrome because some other diagnostic features of the disease such as livedo reticularis, thrombocytopenia, low-titer aCL, IgA ACA, or anti-β 2 GP-1 were not included in the criteria for definite APL Data from references 18, 26-28. *Antithrombotic therapy should not be stopped unless the ACAs has been absent for the preceding 4 to 6 months. † 
Type of Thrombotic Syndrome
Clinical Presentation Recommended Antithrombotic Therapy syndrome. Therefore, classification criteria for "probable" or "possible" APL syndrome should be described to better understand the boundaries of APL syndrome and the full spectrum of "true" APL syndrome (329) . At the subsequent workshop on classification criteria held in Tours, France in September 2000, no alterations were added to the Sapporo criteria. However, future efforts should be focused on the following to improve them: 1) further evaluation of the international (Sapporo) criteria for definite APL syndrome; 2) definition of other categories of APL syndrome, such as "probable" and "possible" APL syndrome; 3) guidelines for the clinical diagnosis as distinct from classification of APL syndrome; 4) strategies to improve the compliance of laboratories worldwide, with recommended procedures for LA and ACA assays; 5) development of monoclonal antibody standard reagents for ACA and LA assays; and 6) refinement and subsequent evaluation of anti-β 2 GP-1 assays for use in identification of APL syndrome (331) . Because the major features of primary and secondary APL syndromes are similar and SLE is by far the most CURRENT DEBATES IN ANTIPHOSPHOLIPID SYNDROME 109 In studies of populations of patients who have more than 1 type of pregnancy morbidity, investigators are strongly encouraged to stratify groups of subjects according to a, b, or c above.
Laboratory criteria
1. Anticardiolipin antibody of IgG and/or IgM isotype in blood, present in medium or high titer, on 2 or more occasions, at least 6 weeks apart, measured by a standardized enzyme-linked immunosorbent assay for beta 2 -glycoprotein I-dependent anticardiolipin antibodies. Data from reference 231. No exclusions other than those contained within the above criteria are needed. However, because of the likelihood that thrombosis may be multifactorial in patients with the APL syndrome, the workshop participants recommend that (a) patient populations being studied should be assessed for other contributing causes of thrombosis, and (b) such populations should be stratified according to identifiable or probable risk factors, e.g., age or comorbidities. Specific limits were not placed on the interval between the clinical event and the positive laboratory findings. However, it was the view of many at the workshop that (a) information about such intervals should be assessed when relevant, and (b) the relatively strict definition of laboratory criteria (including the requirement that results again be positive on repeat tests performed at least 6 weeks after the initial test) would help to exclude antiphospholipid antibody positivity that represents an epiphenomenon to the clinical events.
common cause of secondary APL syndrome, exclusion criteria have been proposed for the diagnosis of primary APL syndrome (Table 4 ) (332) .
CLINICAL STRATEGIES AGAINST APL SYNDROME: OBSERVATION AND RATIONAL CLINICAL MANAGEMENT
Despite tremendous advances in our understanding the pathogenesis of APL syndrome, the mainstay of the management is still anticoagulation. Available data for making a decision on how to treat APL syndrome patients largely come from retrospective studies, and data from prospective clinical trials are limited. Moreover, there is no consensus regarding the duration and intensity of anticoagulant therapy after the thrombotic event occurred. Management strategies based on "Bick classification of APL syndrome" have been given in Table 2 . This classification offers a useful tool for the management of APL in clinical practice.
Whether or not to treat asymptomatic healthy individuals with APL antibodies (type VI disease in Bick's classification) is also a matter of debate. A weakly or transiently elevated positive APL antibody test result needs no prophylaxis. Asymptomatic healthy subjects with persistently positive moderate-to-high titer APL antibodies are generally given low-dose aspirin (ASA 75-100 mg/day). Low-dose aspirin alone could offer some benefit in recurrent miscarriage syndrome with APL antibodies (333) (334) (335) . Aspirin prophylaxis could also provide protection against postpartum non-pregnancy-related vascular thrombosis in APL syndrome patients who present with pregnancy loss as their only manifestation (336) . Prophylactic aspirin is suggested to all patients with SLE to prevent both arterial and venous thrombotic manifestations, especially those with APL antibodies (337) . On the other hand, the use of low dose aspirin in people with ACAs did not protect against deep venous thrombosis or pulmonary embolism (41). Currently there is still no satisfactory prospective evidence that low-dose aspirin provides an adequate prophylaxis against thrombosis especially in venous site in asymptomatic carriers of APL antibodies. Hydroxychloroquine can decrease the titers of APL antibodies and could protect against thrombotic risk in SLE patients. It was also tried in primary APL syndrome in some studies (338, 339) . However, usefulness in asymptomatic carriers of APL antibodies has not been proven by prospective trials. Moreover, the majority of asymptomatic carriers of APL antibodies do not develop thrombotic manifestations. Therefore targeted education and close monitoring of those persons would be appropriate (18, 26, 340) . Clearly, any acquired prothrombotic risk factors should be removed if possible. Asymptomatic individuals with APL antibodies should be examined for the co-existence of hereditary thrombophilia (factor V Leiden, prothrombin 20210A, MHTFR, and others) and a strong family history of arterial and/or venous thrombotic tendency. Selected cases among that specific subpopulation are subject to long-term low-dose aspirin prophylaxis. Likewise, if any asymptomatic subject does develop some clinical features of APL syndrome such as migraine, livedo reticularis, dizzy or confusional episodes, nonspecific visual disturbance, or very early pregnancy loss, low-dose aspirin may be given (340, 341) .
Treatment of acute thrombotic events of patients with APL syndrome is not different than treatment of acute thrombosis in the general population. Those patients should be anticoagulated with standard heparin protocol (339, 342) . However, initial management of acute arterial thrombosis, particularly cerebrovascular events, must include careful differential diagnosis. Stroke during the course of APL syndrome could either be in situ thrombotic or be embolized from the cardiac valves. A hemorrhagic stroke must be ruled out in patients who are already on warfarin prophylaxis. In cases of secondary APL syndrome associated with SLE, possibility of a neurologic involvement due to SLE may further complicate the clinical situation (339) . There are anecdotal reports for successful results with thrombolytic agents or angioplasty in patients with APL syndrome and acute myocardial infarction (343) (344) (345) . However, reocclusion is a major problem and thrombolytic agents are often unhelpful in acute thrombotic events in APL syndrome as well as serious hemorrhagic complications (340) .
There is almost always an increased risk of recurrence of thrombosis in APL syndrome unless effective antithrombotic prophylaxis is given (1, 18, (26) (27) (28) 54, 148, 238, 252, 339, 346, 347) . Corticosteroids or immunosuppresants have no room in reducing thrombotic risk in patients with primary APL syndrome. The immunosuppression generally will not alleviate propensity to thrombosis in secondary APL syndrome patients (18, 26, 348) . Therefore, long-term anticoagulation as a secondary prophylaxis is mandatory in APL syndrome, although the duration and intensity is still controversial. Initial data from large retrospective trials concluded that lifelong highintensity warfarin (i.e. INR ≥ 3.0) is necessary for preventing recurrences (51,346). However, severe hemorrhagic complication appears to be an important problem particularly with high INRs (54, 342, 346, 349) . The risk of major bleeding increases by 42% with every increase in INR by one point (350) . Some small studies suggest that intermediate intensity warfarin therapy (i.e. INR value between 2.0 and 3.0) can be equally effective and safer (238, 252, 347) . Efficacy of inter-mediate-dose warfarin was also supported by its capacity to suppress in vivo markers of coagulation activation, i.e. prothrombin fragments 1+2 (PF 1.2) in patients with SLE and APL antibodies (351) . Recently a randomized, double-blind trial of 114 patients with a mean follow-up period of 2.7 years demonstrated that high-intensity warfarin was not superior to moderate-intensity warfarin for thromboprophylaxis in patients with APL syndrome (352) . Another potential problem with warfarin anticoagulation is dose monitoring because LAs may prolong the PT. In such patients, the INR may not reflect the true level of anticoagulation (353, 354) . Lastly, warfarin failure is not uncommon. Some authors reported that up to 50% of APL patients on adequate doses of warfarin experienced recurrent thrombosis (18,26-28), although warfarin failure could result from inappropriate use or drug interactions (339) . Aspirin may be added to warfarin if there are ongoing symptoms of ischemia despite high-intensity warfarin. However, care should be taken for the increased risk of bleeding in this special therapeutic situation (339) . Low-dose heparin or low-molecular-weight heparin have been suggested as the more effective and safer alternatives to warfarin in the prevention of thrombotic recurrences (18, 26, 28, 355) . Heparin enhances plasmin-mediated inactivation of β 2 GP-1 (356) . Therefore, some authors prefer to use long-term low-molecular-weight heparin (LMWH) therapy for preventing thrombotic recurrences (18, 26, 28, 355) . This LMWH approach may be particularly useful for patients with arterial thrombosis.
There is no consensus on the duration of anticoagulation. Although initial reports suggested lifelong oral anticoagulation, this approach could carry a high risk of bleeding (54,346). Therefore, the risk to benefit ratio and the risk of thrombosis versus bleeding should be evaluated with maximum caution from the clinical point of view. Aspirin alone is an insufficient prophylaxis for the prevention of recurrent arterial or venous thrombosis (346) . Clopidogrel has been effective in stable patients not failing to respond to LMWH (18,26). Therefore, long-term clopidogrel may be an alternative to long-term anticoagulation, particularly in arterial thrombosis (18,26). The duration of antithrombotic treatment may be concluded depending on the clinical severity of the initial thrombotic event and the persistence of antibodies. Some experts prefer to change anticoagulant treatment to antiaggregant prophylaxis with either low-dose aspirin or clopidogrel after 6 months of thrombosis-free and antibodyfree period (18, 26) .
Anticoagulant therapy should be individualized in APL patients depending on the severity of the clinical condition and the localization and nature of the initial thrombus. The Bick classification of APL antibody-associated thrombotic syndromes offers a very useful guide for choosing appropriate therapy for the clinician against the very heterogenous presentations of APL syndrome ( Table 2) .
Thrombocytopenia
Thrombocytopenia rarely causes clinical problem of hemorrhage in APL syndrome. However, it is essential to achieve a platelet count above 50,000 per mm 3 (54) before warfarin therapy to reduce the risk of hemorrhage. Prednisone is the most common approach for management of autoimmune thrombocytopenia in APL syndrome. Intravenous immunoglobulin (IVIG), chloroquine, low-dose heparin, cyclosporin A, dapsone, and danazol have been used to correct thrombocytopenia in APL syndrome in selected cases (339, 341, (357) (358) (359) . Aspirin administration should be given with caution for the damaged function of already low-count platelets in thrombocytopenic APL syndrome. Splenectomy might be indicated, but is occasionally ineffective (148,339).
Management of Pregnancy in APL Syndrome
Women with APL syndrome have a high risk of recurrent fetal loss. Therefore, therapy with aspirin, heparin, prednisone, intravenous immunoglobulin (IVIG), and their combinations have been tried in the obstetric APL syndrome with varying success (226, 230, 360) .
There is a general consensus that women with APL syndrome and a history of thrombosis should receive heparin for thromboprophylaxis during the gestational period because pregnancy represents a hypercoagulable state (340, 361) . However there is no agreement regarding the management of the pregnancies of women with APL antibodies and recurrent miscarriages but had not experienced any previous thrombotic event. There are conflicting data concerning this difficult topic. Earlier non-randomized trials suggested that low-dose aspirin alone is beneficial (333, 334) . A recent randomized controlled trial supported this observation. This trial demonstrated that a high success rate can be achieved with low-dose aspirin only, while LMWH addition do not significantly improve pregnancy out-come (335) . On the other hand, treatment with aspirin plus heparin led to a significantly higher rate of live births in women with APL syndrome than that achieved with aspirin alone in other prospective studies (362, 363) . At the end of the research spectrum, a placebo-controlled study claimed that low-dose aspirin has no additional benefit when added to supportive care for women for whom recurrent early fetal loss is the only sequela of the APL syndrome (364) . However, most of those studies investigated a limited number of subjects and there are some limitations in the research design. Further large randomized placebo controlled trials are needed to identify the optimal treatment for this group of women, although the heterogeneous nature and critical clinical points in fetal and maternal life can limit their performance. Currently, heparin administered to pregnant women after ultrasonographic demonstration of a live embryo is the treatment of choice (1) . LMWH can also be used instead of standard heparin to reduce the risk of osteoporosis and heparin-induced thrombocytopenia (1, 365) . However, maximum care should be taken while choosing the LMWH during pregnancy. Enoxaparin prophylaxis resulted in prosthetic valve thrombosis in two of the seven pregnant women with prosthetic heart valves leading to maternal and fetal deaths. There are other similar postmarketing reports of complications of enoxaparin treatment miscarriages (The FDA Safety Information and Adverse Event Reporting Program, 2002 Safety Alert-Lovenox). Therefore, enoxaparin should not be recommended to manage the pregnancy in APL antibody positive women with a history of recurrent miscarriages. Dalteparin may represent a safer alternative as a LMWH in this setting of APL syndrome complicating pregnancies.
Damage to the developing trophoblast occurs early in the pregnancy. Hence, in most of the experienced centers, aspirin is being started before conception (18, 26, 361) . The success rate of pregnancy using low-dose aspirin and low-dose heparin combination could be as high as 97% (18, 26, 366) . Therefore, this approach should be accepted as "standard of care" until further investigations would be performed focusing on pregnancy and APL syndrome.
Some in vitro observations provide evidence for the rationale of using heparin and aspirin in APL syndrome. APL antibodies affect the invasiveness and differentiation of cytotrophoblast cells after binding to the cell surface. LMWH significantly reduces the immunoglobulin G bind-ing to trophoblast cells and restores in vitro placental invasiveness and differentiation in a dosedependent manner. Such an effect is not observed in the presence of acetylsalicylic acid (367) . LMWH at pharmacologic doses significantly reduces the APL antibody binding and restores gonadotropin releasing hormone-induced human chorionic gonadotropin (hCG) secretion in presence of APL antibody containing sera. Low dose aspirin does not modify APL antibody binding, but partially restores hCG secretion (368) .
Therefore, LMWH together with low-dose ASA offers not only a simple antithrombotic approach but also have the potential to modify the pathobiology of the pregnancy loss due to APL syndrome.
There is also no general agreement on the duration of postpartum thromboprophylaxis. Those women are usually suggested to hold the heparin therapy but to continue low-dose aspirin after delivery depending on the individual clinical situation (18,26). There is an increased risk for non-pregnancy-related vascular thrombosis in APL syndrome patients who present with pregnancy loss as their only manifestation of APL syndrome. Recently a retrospective study suggested that aspirin alone is effective as a prophylaxis in this subgroup of APL syndrome patients (336) .
Prednisone administration during pregnancy of women with APL syndrome provided no benefit over either low-dose heparin or low-dose aspirin. Moreover, steroid use resulted in significant maternal morbidity including gestational diabetes, hypertension, osteoporosis, and preterm labor (333, 369, 370) . Therefore, steroid administration should be restricted to patients with thrombocytopenia or coexistent lupus (361) .
Earlier studies with small numbers of patients implied that addition of IVIG to either aspirin or heparin is safe and might improve the pregnancy outcomes (371, 372) . However, results of a recent multicenter study demonstrated that IVIG failed to improve obstetric or neonatal outcomes beyond those achieved with a heparin and low dose aspirin regimen (373) . Moreover, a more recent randomized study exhibited that APL syndrome women treated with LMWH plus low-dose aspirin had a higher rate of live births than those treated with IVIG (374) . The additional cost of IVIG is also a matter of debate. Therefore, IVIG therapy should only be considered in serious pregnancy-related patient morbidity that is refractory to aspirin plus heparin (230, 360) .
APL syndrome is now accepted as a treatable cause of recurrent pregnancy loss (1) . Seventyfour percent of women who became pregnant in the recently published cohort of 1000 APL patients succeeded in having one or more live births (437 of 590 women). This represents the advances in the treatment and follow-up of APL pregnants (23).
Clinical approach to women with APL antibodies without any symptom of APL syndrome during their first pregnancy is also a matter of debate. The common practice in such cases is low-dose aspirin, although remains to be largely unconfirmed. A small study investigating the efficacy of low-dose aspirin in persistently APL positive women with "low risk" pregnancy (i.e. no associated signs or symptoms of the APL syndrome, thrombosis or thrombocytopenia and no or just one prior spontaneous abortion) failed to demonstrate any advantage of aspirin administration in such pregnants. However, the frequency of complications was so low that at least 600 women were needed for the investigation as to whether low-dose aspirin would be beneficial treatment during a pregnancy (375) .
Management of Catastrophic APL Syndrome
Catastrophic APL syndrome is a life-threatening medical emergency that requires high-level clinical awareness. Varying combinations of anticoagulants, steroids, plasmapheresis, cyclophosphamide, and IVIG were administered for the management of this condition (232, 233) . Among the 20 patients who received a combination of antithrombotics, steroids, and plasmapheresis or IVIG, recovery occurred in 14 (70%) patients in a previous study (232) . Fibrinolytic agents have been tried to treat acute thrombotic microangiopathy (232) . Recently, an international consensus statement for treatment guidelines for catastrophic APL syndrome was established by the Catastrophic APL Syndrome Registry Project Group during the presymposium workshop on APL syndrome consensus, held in Taormina at the tenth International Congress on APL syndrome in September 2002. The optimal management of catastrophic APL syndrome must have three clear aims according to this consensus report: to treat any precipitating factors (prompt use of antibiotics if infection is suspected, amputation for any necrotic organ, high awareness in patients with APL syndrome who undergo an operation or an invasive procedure); to prevent and to treat the ongoing thrombotic events; and to suppress the excessive cytokine "storm." Standard anticoagulation protocol (usually intravenous heparin followed by oral anticoagulants), corticosteroids, plasma exchange, intravenous gammaglobulins and, if associated with lupus flare, cyclophosphamide, are the most commonly used treatments for catastrophic APL syndrome patients (376) .
FUTURE PROSPECTS
Better standardization of diagnostic tests is mandatory particularly for the detection of clinically suspected cases. Moreover, we still need better predictive assays to differentiate diseaseassociated APL antibodies to identify which patients with APL antibodies are truly at risk for thrombotic events. Identification of peptide mimetics for each immunologically distinct prothrombotic APL antibodies seem to help us for this aim (377) . Molecular markers of thrombosis, such as PF 1.2, could be investigated with prospective large trials in asymptomatic carriers of APL antibodies to identify the "high-risk" subjects (378) . The prospective study of aspirin as compared with placebo, and the trial of aspirin as compared with low-dose warfarin plus aspirin would give us more dependable answers to the question of whether to treat individuals with APL antibodies in the clinically "gray" zone (379, 380) . Results of ongoing large collaborative prospective randomized double-blind studies (such as (WAPS, PAPRE, WARSS, APASS, PRE-CLUDE trials) are being awaited for more efficient and less toxic therapeutic approaches (339, 347, 381) . Statins blocked APL antibody-induced endothelial cell activation in vitro and diminished APL antibody-mediated thrombosis and endothelial cell activation in an in vivo animal model (382, 383) . Hence, statins might serve as complementary medicines for the management of APL syndrome. Focusing on better understanding of the pathobiology of the APL syndrome may further provide new therapeutic strategies. For instance, intensive antioxidant therapy, antithrombotic strategies that more specifically target the tissue factor pathway of coagulation such as recombinant tissue factor pathway inhibitor or anti-tissue factor antibodies, or a β 2 GP-1-specific B cell toleragen, LJP 1082, may be tried for more specific targeted therapy (299, 384, 385 
